Milne, Ross

Overview 

Ross Milne is Director of the Diabetes and Atherosclerosis Laboratory at the University of Ottawa Heart Institute. He is also a Professor in the Departments of Pathology and Laboratory Medicine, and Biochemistry, Microbiology and Immunology at the University of Ottawa.

Background 

Milne received a PhD in Immunology from McMaster University in Hamilton, Ontario, in 1976. With the support of a Post-doctoral Fellowship from the Medical Research Council of Canada, he then spent four years in the International Institute of Cellular Pathology at the Université Catholique de Louvain in Brussels. There, he worked in the laboratory of Dr. Jean Pierre Vaerman. In 1980, he joined the Lipoprotein Metabolism Laboratory at the Institut de Recherches Cliniques de Montréal and obtained a faculty appointment at the Université de Montréal. In 1992, he moved to the University of Ottawa to help establish the Lipoprotein and Atherosclerosis Research Group.

Research & Clinical Interests 

Milne’s primary research interest is the metabolism of plasma lipoproteins and their role in atherosclerosis. Specifically, he has studied apolipoproteins and their cell surface receptors, and plasma lipid transfer proteins.

Currently, Milne’s laboratory is investigating the role of advanced glycation end products (AGEs) in diabetic cardiovascular disease. To better characterize the contribution of AGEs in disease, Milne and his colleagues have developed a novel mouse line that carries a human GLO-1 transgene. They are testing the hypothesis that the increased GLO-1 activity in the transgenic mice will lower MG and AGE concentrations and provide protection in mouse models of diabetic atherosclerosis and diabetic retinopathy.

Another major project in the laboratory is to identify novel intracellular molecules and mechanisms involved in receptors for AGE signal transduction. These projects should lead to new therapeutic targets for alleviating the complications of diabetes.

Publications 

LATEST PUBLICATIONS

  • Liao W, Strube RW, Milne RW, Chen SC, Chan L. Cloning of apoB intrabodies: specific knockdown of apoB in HepG2 cells. Biochem Biophys Res Commun 2008;373:235-240.
  • Kiss RS, Kavaslar N, Okuhira KI, Freeman MW, Walter S, Milne RW, McPherson R, Marcel YL. Genetic etiology of isolated low HDL syndrome: incidence and heterogeneity of efflux defects. Arterioscler Thromb Vasc Biol 27 2007;1139-1145.
  • Heath RB, Karpe F, Milne RW, Burdge GC, Wootton SA, Frayn KN. Dietary fatty acids make a rapid and substantial contribution to VLDL-triacylglycerol in the fed state. Amer J Physiol Endocr Metab 2007;292:732-739.
  • Braschi S, Geoffrion M, Nguyen A, Gaudreau Y, Milne RW. Apolipoprotein B (apoB) modified by glucose in vitro differs from apoB in the circulation of patients with diabetes or end-stage renal disease. Diabetologia 49 2006;1394-1401.
  • Nguyen AT, Hirama T, Chauhan V, MacKenzie R, Milne RW. Binding characteristics of a panel of monoclonal antibodies against the ligand-binding domain of the human LDL receptor. J Lipid Res 47 2006;1399-1405.

FULL LIST OF PAPERS IN REFEREED JOURNALS

  • Braschi, S. Geoffrion, M., Nguyen, A., Gaudreau, Y. AND Milne, R.W. (2006) Apolipoprotein B (apoB) modified by glucose in vitro differs from apoB in the circulation of patients with diabetes or end-stage renal disease. Diabetologia. 49, 1394-1401.
  • Nguyen, A.T., Hirama, T., Chauhan, V., MacKenzie, R., Milne, R.W. (2006) Binding characteristics of a panel of monoclonal antibodies against the ligand-binding domain of the human LDL receptor. J. Lipid Res. 47, 1399-1405.
  • Heath, R.B., Karpe, F., Milne,R.W. Burdge, G.C., Wootton, S.A., AND Frayn, K.N. (2007) Dietary fatty acids make a rapid and substantial contribution to VLDL-triacylglycerol in the fed state. Amer. J. Physiol. Endocr. Metab. 292 732-739.
  • Kiss, R.S., Kavaslar, N., Okuhira K.I., Freeman, M.W., Walter, S., Milne, R.W. McPherson, R., AND Marcel, Y.L. (2007) Genetic etiology of isolated low HDL syndrome: incidence and heterogeneity of efflux defects. Arterioscler. Thromb. Vasc. Biol. 27, 1139-1145.
  • Liao, W., Strube, R.W., Milne, R.W. Chen, S.C., AND Chan, L. (2008) Cloning of apoB intrabodies: specific knockdown of apoB in HepG2 cells. Biochem. Biophys. Res. Commun. 373, 235-240.
  • Wang, X., Chauhan, V., Nguyen, A.T., Schultz, J., Davignon, J., Young, S.G., Borén, J. Innerarity, T.L., Rutai, H. and Milne, R.W. (2003) Immunochemical evidence that human apoB differs when expressed in rodent versus human cells. J. Lipid Res. 44, 547-553.
  • Raffaï, R., McPherson, R., Weisgraber, K.H., Innerarity, T.L., Rassart, E., Bersot, T.P. AND Milne, R.W. (2003) Antibody phenotyping test for the human apoE2 isoform. Clin. Chem. 49, 1524-1526.
  • Ath, R.B., Karpe, F., Milne, R.W., Burdge, G.C., Wootton, A., AND Frayn, K.N. (2003) Selective partitioning of dietary fatty acids into the VLDL-TG pool in the early postprandial period. J. Lipid Res. 44, 2065-2072.
  • Gauthier, A., Lau, P., Zha, X., Milne, R., AND McPherson, R. (2005) Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver. Arterioscler. Thromb. Vasc. Biol. 25, 2177-2184.
  • Nguyen, A.T., Braschi, S., Geoffrion, M., Fong, L.G., Crooke, R.M., Graham, M.J., Young, S.G., AND Milne, R. (2006) A mouse monoclonal antibody specific for mouse apoB48 and apoB100 produced by immunizing "apoB39-only" mice with mouse apoB48. Biochim. Biophys. Acta. 1761, 182-185.

Share This